Kessler Topaz Meltzer & Check, LLP Reminds MGNX Investors of September 24, 2024 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the Firm

Core Viewpoint - A securities class action lawsuit has been filed against MacroGenics, Inc. for allegedly making false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of investors who purchased MacroGenics stock or sold puts between March 7, 2024, and May 9, 2024 [1]. - The lead plaintiff deadline for the lawsuit is September 24, 2024 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants created a materially misleading impression regarding the safety profile of vobramitamab duocarmazine and the overall data from the Phase 2 TAMARACK study [2]. Group 3: Lead Plaintiff Process - Investors in MacroGenics can seek to be appointed as a lead plaintiff representative of the class by the deadline of September 24, 2024, or may choose to remain an absent class member [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3]. Group 4: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].